tailieunhanh - Báo cáo y học: "Protective effect of budesonide/formoterol compared with formoterol, salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma: a randomised, double-blind, cross-over study"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài: "Protective effect of budesonide/formoterol compared with formoterol, salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma: a randomised, double-blind, cross-over study. | Aalbers et al. Respiratory Research 2010 11 66 http content 11 1 66 RESPIRATORY RESEARCH RESEARCH Open Access Protective effect of budesonide formoterol compared with formoterol salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma a randomised double-blind cross-over study René Aalbers1 Martin Boorsma2 Hanneke J van der Woude1 and René E Jonkers 3 Abstract Background The budesonide formoterol combination is successfully used for fast relief of asthma symptoms in addition to its use as maintenance therapy. The temporarily increased corticosteroid dose during increasing inhaler use for symptom relief is likely to suppress any temporary increase in airway inflammation and may mitigate or prevent asthma exacerbations. The relative contribution of the budesonide and formoterol components to the improved asthma control is unclear. Methods The acute protective effect of inhaled budesonide was tested in a model of temporarily increased airway inflammation with repeated indirect airway challenges mimicking an acute asthma exacerbation. A randomised double-blind cross-over study design was used. Asthmatic patients n 17 mean FEV1 95 of predicted who previously demonstrated a 30 fall in forced expiratory volume in 1 second FEV1 after inhaling adenosine 5 -monophosphate AMP were challenged on four consecutive test days with the same dose of AMP at 09 00 12 00 and 16 00 hours . Within 1 minute of the maximal AMP-induced bronchoconstriction at 09 00 hours the patients inhaled one dose of either budesonide formoterol 160 pg formoterol pg salbutamol 2 X 100 pg or placebo. The protective effects of the randomised treatments were assessed by serial lung function measurements over the test day. Results In the AMP provocations at 3 and 7 hours after inhalation the budesonide formoterol combination provided a greater protective effect against AMP-induced bronchoconstriction compared with formoterol alone salbutamol and